## The Tide Goes Out: asset allocation, equity mutual funds and hedge funds after the growth stock selloff

**Russia.** This interview in Italian daily Corriere della Serra is a disturbing look at the world according to Russia, as per Putin/Yeltsin advisor Sergey Karaganov. It's entitled "<u>We are at war with the West. The European security</u> <u>order is illegitimate</u>". In addition to Karaganov's arguably distorted and at times absurd view of history, note his belief that Russia will eventually launch attacks on European countries supplying arms to Ukraine.

**Market update**. As I wrote in the March *Eye on the Market*, we expect the March 15 equity market lows to hold as long as there is no US recession. Some recession indicators are rising: first inverted 2-year to 30-year yield curve since 2007; a collapse in consumer sentiment to one of the lowest levels in 70 years; declining small business surveys; and ISM business survey orders falling below inventory levels for the first time since the expansion began. In addition, more signs of prolonged goods shortages and inflation: China's supply chain delays and spikes in anchored containerships due to COVID, and additional sanctions on Russia in response to what has been described as executions, torture and other war crimes committed by Russian soldiers. Even so, I think a low growth period in 2022 in the US is more likely than a recession. Labor markets are very tight (there has never been a recession without a large spike in jobless claims), household and corporate balance sheets are in very good shape, and the release of the Strategic Petroleum Reserve lowers risk of recession in the near term (though it's still a bullish sign for oil prices in the medium term). US recession risks look higher for 2023-2024.

**The Tide Goes Out: Growth Trade Aftermath**. As of February 28<sup>th</sup>, the median NASDAQ stock was down ~40% from its prior peak, a consequence of rising interest rates and the unsustainable increase in unprofitable companies. These declines are large but pale in comparison to the 2001-2002 selloff when the median NASDAQ stock was down ~75% from its peak, and when growth outperformance vs value was completely erased (this time growth has only given up a modest amount of its outperformance vs value). In this note, we look at asset allocation, equity mutual fund and hedge fund performance after the growth stock selloff.

#### **Rising rates**





Percent of stocks in index (NASDAQ n = 2912, R1000G n =452)



The YUCs: young unprofitable companies % of equity market capitalization



Next Eye on the Market: our 12th annual energy paper. Topics include a critical look at widely cited use cases for green hydrogen, China's coal fixation, the US transmission quagmire, electric heat pumps, the sharp recovery in oil & gas stocks relative to renewable stocks since mid-2020, US gasoline super-users and lessons from Europe about the journey to a renewable energy future.

Past performance is no guarantee of future results. It is not possible to invest directly in an index.

INVESTMENT PRODUCTS ARE: • NOT FDIC INSURED • NOT A DEPOSIT OR OTHER OBLIGATION OF, OR GUARANTEED BY, JPMORGAN CHASE BANK, N.A. OR ANY OF ITS AFFILIATES • SUBJECT TO INVESTMENT RISKS, INCLUDING POSSIBLE LOSS OF THE PRINCIPAL AMOUNT INVESTED

Analysis summary: a growth allocation generated substantial excess returns in pro-forma portfolios from 2017 to Feb 2022, even after the selloff. However, the four largest mega-stocks (Apple, Microsoft, Amazon and Google) accounted for almost half of these excess returns. Furthermore, only top quartile equity mutual fund and hedge fund managers delivered excess returns versus their growth benchmarks.

## Asset Allocation: still a clear benefit from growth stock exposures in portfolios

To assess the benefit of an allocation to growth in equity portfolios, we compare an investment in the Russell 1000 Growth Index and the NASDAQ to other equity alternatives such as the S&P 500, Value stocks, Europe, US/Global Small Cap and Emerging Markets. The timeframe is of course a critical decision; looking back at our investment commentary over the last few years, I picked January 2017 as a starting point since that's when we began to focus on the higher revenue growth and profit margins of tech and healthcare in a slower growth world. Different starting dates would of course yield different results.





Source: Bloomberg, JPMAM. April 7, 2022.

Source: Bloomberg. April 7, 2022.

Closer look at the Russell 1000: growth outperformed but

Results. Through the end of February 2022, an allocation to growth generated higher returns than the other options shown with comparable levels of volatility. However, almost 50% of growth's outperformance vs value was derived from exposure to the largest four stocks (AAPL, MSFT, AMZN, GOOG). For investors executing this view through passive index products, the performance discussion would stop here other than having to account for passive index fees which are generally comparable across the indexes shown<sup>1</sup>.

	Russell 1000 Growth	NASDAQ	Russell 1000 Value	Russell 2000 Small Cap	S&P 500	MSCI Europe	MSCI World Small Cap	MSCI Emerging markets
Cumulative return	171%	168%	64%	61%	115%	50%	66%	52%
Return (ann)	21%	21%	10%	10%	16%	8%	10%	8%
Volatility (ann)	17%	18%	16%	21%	16%	16%	19%	16%
Return / Risk	1.2x	1.2x	0.6x	0.5x	1.0x	0.5x	0.6x	0.5x
Cur value / peak	88%	88%	97%	89%	92%	93%	91%	86%

### Growth equity vs other equity benchmarks. January 2017 - February 2022

Source: JP Morgan Private Bank, Bloomberg. February 2022.

<sup>&</sup>lt;sup>1</sup> ETF fees generally range from 3 to 20 basis points for US equity ETFs. Global Small Cap ETF fees are around 45 basis points, and Emerging Market ETF fees are closer to 70 basis points

# Growth equity mutual funds: outperformance is scarce as diversification hurt returns

Assessing mutual fund performance is a straightforward exercise:

- Use Morningstar to obtain a universe of funds in the Large Cap Growth category, excluding passive products
- Narrow to those funds with performance from Jan 2017 to Feb 2022. This does create a survivorship bias issue since we ignore funds that used to be in this category but dropped out for whatever reason
- Use the lowest fee share class for each fund as a proxy for its Institutional share class, and compute cumulative performance from 2017-2022
- Compute excess returns for each fund relative to its stated benchmark. Most growth managers use the Russell 1000 Growth Index; others use the S&P 500 and a few use the Russell 3000 Growth Index

*Results*. Most funds with a R1000 Growth benchmark underperformed over this period. Many may have been reluctant to hold index-weight positions in the four largest stocks whose performance more than doubled the performance of growth stocks in recent years. Managers may also have been discouraged from doing so for regulatory reasons (see box). In March, the largest weights in the R1000 Growth index were AAPL 12.5%, MSFT 10.8%, AMZN 6.6%, GOOG 6.4%. As a result, just holding market weight positions would imply 36% in these four stocks, above the 25% diversification threshold that many mutual funds seek to comply with<sup>2</sup>, requiring them to be structurally underweight. As shown in the third chart, we estimate the cost of the diversification rule applied to the Russell 1000 Growth Index to be ~15% over the time horizon.



Relative cumulative performance (Jan 2017 - Feb 2022) Source: JPMAM. February 2022.





Performance of four largest stocks more than doubled Growth index performance since 2017, Index (100 = Jan 2017)



#### Diversification Rule of the 1940 Investment Company Act

Many 40 Act mutual fund managers seek to meet a **diversification test** which requires positions that are over 5% to sum to less than 25% of the fund. [Section 5-b-1]

Certain investor types such as Defined Contribution plans generally prefer funds that pass the diversification test.

If a diversified fund actively breaches the threshold, any securities purchased that caused the violation would need to be sold. Any losses would be reimbursed to the fund while any gains would be kept by the fund.

<sup>&</sup>lt;sup>2</sup> A mutual fund benchmarked to the S&P 500 Growth Index would face a similar problem: AAPL 14%, MSFT 12%, AMZN 7% and GOOG 8%. In other words, 41% of the index and well above the 25% threshold.

In contrast, most growth mutual funds using an S&P 500 benchmark *outperformed*. This may reflect the presence of core managers whose growth tilt was so high as to push them into Morningstar's growth category, but the manager still benchmarks their performance to the S&P 500 Index. Whether investors give managers with a strong growth tilt credit for outperformance vs a core benchmark is up to them. Not sure I would.



Performance was mixed for the smaller number of mutual funds categorized by Morningstar as "growth" and who benchmark their performance to the Russell 3000 Growth Index. Given the underperformance of small cap shown on page 2 over this period, any manager with a structural underweight to small cap growth would have generated substantial excess returns over benchmark.

For legal and compliance reasons, I cannot cite JP Morgan Asset Management's large cap growth performance; you will have to look that up on your own.

# Hedge fund performance: plenty of assumptions and triangulation required

Measuring long only equity and fixed income mutual fund performance against stated benchmarks is a simple process. The prior section is one example of that.

As for private equity and venture capital, the development of the LP-sourced Burgiss performance database now allows for proper time-weighted performance measurement versus a variety of public equity market benchmarks without having to worry about survivorship bias or selective reporting. We discussed this in last year's <u>deep dive on private equity and venture capital</u>. There is no easy answer to the question of what kind of illiquidity premium is "fair" to investors, but at least the magnitude of what investors earn in private equity and venture capital relative to public equity markets is much clearer.

In contrast, deciding whether a given hedge fund has performed well or not relative to its opportunity set is one of the more complicated questions in investment finance. The "LIBOR plus a spread" benchmark and the HFRI benchmarks that were popular in the 1990's are used less often now, and the "stock/bond mix" benchmark approach is used less often as well. When investors have look-through access to a hedge fund's exposures on a daily or weekly basis, they can construct a customized benchmark based on market factors to assess performance. But that is not a viable option when doing industry-level analysis with monthly data.

As a result, I'm going to use a simple approach to benchmark hedge fund performance. Many growth longshort hedge funds have "observed market betas" of ~0.45 relative to the Russell 1000 Growth index. In other words, over the long run their returns rise and fall at 45% of the rate of the Russell Index itself. So, we use 0.45 of the Russell 1000 Growth as a benchmark for growth long short hedge funds in this analysis. We sometimes look at a NASDAQ benchmark as well but since its performance is almost identical to the R1000 Growth Index, we only show the R1000 Growth benchmark in the charts and tables that follow. Note in the last chart how the beta-adjusted R1000 Growth benchmark is similar to a 50% S&P 500 / 50% Barclays Aggregate benchmark.



Hedge fund benchmark comparison



**Russell 1000 Growth vs NASDAQ performance** Total return index (100 = Jan 2017)



# Then there's the challenge of obtaining hedge fund performance data in the first place

Unlike the Burgiss database of LP-sourced private equity and venture capital flows, no such database exists for hedge funds. There are several aggregators that compile hedge fund performance but they all rely on hedge funds to consistently report their performance, and **many of the largest hedge funds simply have no interest in doing that**. Hedge fund managers provide performance history to investors considering an allocation, but such data is often subject to non-disclosure agreements that prevent it from being used for research publications like this one.

Once we obtain hedge fund performance data, there are still issues that make returns harder to compare. Some managers have **large private exposures** as high as 50% of the fund's NAV. When public equity markets decline, private exposures are often not repriced as quickly, making comparisons across funds harder. And of course, **gross and net leverage differ** across funds as well.

As a result, we have to triangulate and use **four separate self-reported universes of hedge fund monthly returns from January 2017 to February 2022**<sup>3</sup>. Our Asset Management's Hedge Fund Due Diligence team considers the first two more indicative of an institutional peer group, and shares the same reservations I have regarding the HFR dataset due to the lack of data from some of the largest well known funds.

- Long-short hedge funds categorized by PivotalPath as "Tech-focused"
- Long-short generalist growth hedge funds identified by JP Morgan Asset Management's Hedge Fund Due Diligence team as "Tiger Cubs" in the PivotalPath database<sup>4</sup>
- Long-short hedge funds categorized by HFR as "Technology" or "Healthcare" (note: we do not use the HFR Equity Hedge Growth category since it includes a lot of hedge funds investing in Emerging Markets)
- Long-short hedge funds in the eVestment database with observed market betas of at least 0.45 vs the S&P 500 Growth Index (eVestment does not have a Growth category, which is why we chose this method)

For each hedge fund universe, we identify the median, 75<sup>th</sup> percentile and 25<sup>th</sup> percentile manager<sup>5</sup>. For each of these managers, we show annualized returns, annualized volatility, return/risk, the fund's current NAV vs peak levels (i.e., drawdown) and its correlation with the Russell 1000 Growth Index.

Are you excited yet? I am.

<sup>&</sup>lt;sup>3</sup> While the Russell 1000 Growth Index rose by ~4% in March, some hedge funds may trail the beta-adjusted benchmark. The reasons: large caps outperformed small caps in March (often a headwind for hedge funds), an index of widely owned hedge fund positions was up 1% while a basket of stocks with the highest short interest rose by 6%, and while growth outperformed value, telecommunications services were up less than 1%. Finally, hedge funds with large private positions may still need to mark some of them down.

<sup>&</sup>lt;sup>4</sup> PivotalPath does not have every manager we know to be a Tiger Cub descendent, but they do have what we consider to be a large representative sample.

<sup>&</sup>lt;sup>5</sup> We equal-weight rather than asset-weight funds. As a result, we may include smaller funds with less industry impact. Asset-weighting can be problematic: what about a fund with large assets under management (AUM) at inception which then underperforms and suffers substantial outflows? If the ending AUM is used, it understates their impact. The same problem exists using inception AUM for managers that accumulate assets. Timeweighted AUM is better than using inception or ending AUM; but equal weighting is our preferred approach.

# Hedge fund performance based on PivotalPath data

PivotalPath has data for 104 Technology long-short funds. However, many of these funds do not have consistent monthly data over our time horizon. We ended up with just 27 that we could analyze out of the original 104; some excluded funds began after January 2017, while others stopped reporting before February 2022. Data limitations are a frustrating and inescapable part of the hedge fund landscape.

The performance distribution looks "normal": median Technology long-short hedge fund returns were close to our beta-adjusted growth benchmarks and also generated higher risk-adjusted returns. The 75<sup>th</sup> percentile manager's outperformance was slightly larger than the 25<sup>th</sup> percentile manager's underperformance.

# PivotalPathTech hedge funds, N=27



				45% net
PivotalPath Tech fund p	exposure			
	25th	50th	75th	Russell 1000
		ootiii		Growth
Cumulative return	37%	63%	90%	60%
Return (ann)	6%	10%	13%	9%
Volatility (ann)	9%	6%	13%	8%
Return / Risk	0.7x	1.6x	1.0x	1.2x
Cur value / peak	88%	97%	90%	94%
Correl w Russ 1000 Gr	58%	36%	50%	

Source: PivotalPath, JPMAM. February 2022.

We then analyzed the 29 funds in the PivotalPath dataset that our Hedge Fund Due Diligence team identified as generalist growth-oriented "Tiger Cub" descendants of the original Tiger fund. However, PivotalPath only has consistent monthly performance from Jan 2017 to Feb 2022 for 12 of them.

The 75<sup>th</sup> percentile Tiger Cub fund kept pace with our Russell benchmark, while the median manager experienced a correction in Q1 2022 that left the fund well below it. The 25<sup>th</sup> percentile Tiger Cub manager generated weak performance with high levels of volatility relative to returns. Some Tiger Cub funds exhibit very high volatility: one such fund generated very high returns (above the 75<sup>th</sup> percentile over the time horizon) but also generated very high volatility (16%) and experienced a sharp selloff whose drawdown reached 37% by February 2022 (i.e., current value / peak value of 63%). This fund has reportedly experienced further large drawdowns in March despite the recovery in the Russell 1000 Growth Index.





	45% net			
PivotalPath Tiger Cub fu	exposure			
	25th	50th	75th	Russell 1000
	2501	3000	7501	Growth
Cumulative return	14%	37%	60%	60%
Return (ann)	3%	6%	10%	9%
Volatility (ann)	12%	11%	9%	8%
Return / Risk	0.2x	0.6x	1.0x	1.2x
Cur value / peak	82%	79%	92%	94%
Correl w Russ 1000 Gr	39%	61%	68%	

Source: PivotalPath, JPMAM. February 2022.

# Hedge fund performance based on HFR and eVestment data

We were able to analyze 55 out of 96 long short hedge funds in the HFR dataset. As a reminder, we analyzed long-short hedge funds that were categorized by HFR as Technology or Healthcare. The results are similar to the PivotalPath Technology dataset: median manager close to beta-adjusted benchmark, with 75<sup>th</sup> and 25<sup>th</sup> percentile managers distributed on either side of them. Also similar: the 75<sup>th</sup> percentile manager outperformed by more than the 25<sup>th</sup> percentile manager underperformed. But to reiterate, we have concerns about the relevance of this dataset to institutional investors given which funds self-report.

# HFR Tech/Healthcare hedge funds, N=55



				45% net
HFR tech/healthcare fur	exposure			
	25th	50th	75th	Russell 1000 Growth
Cumulative return	31%	65%	126%	60%
Return (ann)	5%	10%	17%	9%
Volatility (ann)	12%	17%	24%	8%
Return / Risk	0.4x	0.6x	0.7x	1.2x
Cur value / peak	90%	93%	85%	94%
Correl w Russ 1000 Gr	61%	40%	72%	

Source: HFR, JPMAM. February 2022.

The eVestment database has a lower rate of missing performance data than the other three datasets. We were able to analyze 231 out of 339 funds in their database. As a reminder, these funds were selected since they exhibited a beta to the S&P 500 Growth Index of at least 0.45 over the last two years. The results in most respects are almost identical to the HFR dataset results shown above.





eVestment high beta fu	45% net exposure			
	25th	50th	75th	Russell 1000 Growth
Cumulative return	38%	66%	103%	60%
Return (ann)	6%	10%	15%	9%
Volatility (ann)	13%	15%	18%	8%
Return / Risk	0.5x	0.7x	0.8x	1.2x
Cur value / peak	79%	92%	82%	94%
Correl w Russ 1000 Gr	60%	66%	90%	

Source: eVestment, JPMAM. February 2022.

# Wrapping up: growth generated substantial asset allocation returns from 2017 to Feb 2022, but only top quartile equity and hedge fund managers delivered excess returns versus growth benchmarks

- Asset allocation. An allocation to growth since 2017 generated benefits in portfolios despite the selloff that took place through February 2022
- *Equity mutual funds*. Most growth mutual funds underperformed the R1000 Growth Index during this period. We believe that this reflects in part mutual fund manager reluctance/inability to hold market weight positions in the largest four stocks which outperformed the rest of the equity market by 300% from 2017 to February 2022, one of the largest such outperformance periods in history
- Hedge fund performance

*Median manager*. Most median hedge fund managers tracked our beta-adjusted growth benchmarks even though they did not hold market-weight positions in the four largest stocks. The Tiger Cub manager was the exception, trailing the benchmark instead

*Underperforming managers*. The 25<sup>th</sup> percentile hedge fund managers all lagged our benchmark, and also generated from 1% to 5% higher volatility

*Outperforming managers*. The 75<sup>th</sup> percentile managers in three of the datasets generated large returns vs our benchmarks; the exception was the 75<sup>th</sup> percentile Tiger Cub fund which tracked the benchmark instead



Source: PivotalPath, HFR, eVestment, JPMAM. February 2022.

- *Volatility*. Some hedge funds that experienced large drawdowns this year accumulated high prior returns, such that long term investors were still ahead of our benchmarks. This context is often missing from press articles<sup>6</sup>. However, volatility and risk may still be understated for funds with large private exposures
- Benchmarks. Using a stock-bond mix or a beta-adjusted equity index is a simple approach that does not take into account the investment style of the manager. Hedge fund researchers often take performance measurement analysis to a deeper level to determine what a fund is doing with its capital, and measuring performance relative to a customized benchmark (see Appendix I). Such an approach is beyond the scope of our industry wide analysis given the limitation of monthly returns
- *Data issues*. Selective reporting, survivorship bias and lack of comparability cloud the results. For the PivotalPath dataset, we were only able to analyze less than half the managers that existed during the time horizon due to missing data. Appendix II reviews the performance of partial managers which we excluded

<sup>&</sup>lt;sup>6</sup> One example: "Selling in speculative tech stocks knocks Tiger Cub hedge funds", Financial Times, March 8, 2022. The article has a table of 2020 and 2021 performance by fund but makes no mention of prior performance. The article does make interesting points about overlapping exposures in certain growth stocks, and allows readers to examine these positions based on fund regulatory filings.

# Appendix I: Factor based hedge fund performance analysis

A large institutional investor can often obtain high frequency returns and leverage directly from a hedge fund. Hedge fund researchers can then regress these returns against market "factors" such as price-to-book, cash flow to enterprise value, price momentum, low volatility, etc. Each factor is constructed as a miniature long-short position; i.e. a price-to-book factor would show the daily returns on a portfolio that owned the "cheapest" stocks (lowest price to book) and was short the most expensive stocks (highest price to book).

If a hedge fund's returns are highly correlated with one or more factors over time, that set of factors can be used as a benchmark with any residual performance differences measuring the manager's excess return vs benchmark. The more customized a factor based benchmark is, the more the hedge fund is being measured against their *assumed* opportunity set. As a result, the benefit or penalty from investing in low volatility or low price to book stocks is assumed to be an asset allocation decision that the manager is not responsible for.

Other approaches require **position-level transparency**, which would allow for a hedge fund researcher to determine how much the fund made from market exposure, sector, country and style preferences, with any residual representing manager excess return.

## Appendix II: Hedge fund survivorship bias and missing data

There's not much we can do about missing data. But for hedge funds we excluded due to incomplete data, we can at least see if there is any performance skew for returns they *did* report during the 2017-2022 time horizon. As shown below, we unsurprisingly found a modest bias towards outperformance in the partial returns that these excluded managers did report. But the missing data remains a mystery, which is why we excluded these managers and their partial returns in the overall analysis.

Number of excluded funds out/underperforming R1000 Growth based on their partially reported returns



Excess ann. return vs Russell 1000 Growth @ 45% net exposure Source: PivotalPath, JPMAM. February 2022.



Excess ann. return vs Russell 1000 Growth @ 45% net exposure Source: HFR, JPMAM. February 2022.

PivotalPath Tech (n = 73 funds)



Excess ann. return vs Russell 1000 Growth @ 45% net exposure Source: PivotalPath, JPMAM. February 2022.





Excess ann. return vs Russell 1000 Growth @ 45% net exposure Source: eVestment, JPMAM. February 2022.

#### Access our full coronavirus analysis web portal here

#### **IMPORTANT INFORMATION**

This report uses rigorous security protocols for selected data sourced from Chase credit and debit card transactions to ensure all information is kept confidential and secure. All selected data is highly aggregated and all unique identifiable information, including names, account numbers, addresses, dates of birth, and Social Security Numbers, is removed from the data before the report's author receives it. The data in this report is not representative of Chase's overall credit and debit cardholder population.

The views, opinions and estimates expressed herein constitute Michael Cembalest's judgment based on current market conditions and are subject to change without notice. Information herein may differ from those expressed by other areas of J.P. Morgan. This information in no way constitutes J.P. Morgan Research and should not be treated as such.

The views contained herein are not to be taken as advice or a recommendation to buy or sell any investment in any jurisdiction, nor is it a commitment from J.P. Morgan or any of its subsidiaries to participate in any of the transactions mentioned herein. Any forecasts, figures, opinions or investment techniques and strategies set out are for information purposes only, based on certain assumptions and current market conditions and are subject to change without prior notice. All information presented herein is considered to be accurate at the time of production. This material does not contain sufficient information to support an investment decision and it should not be relied upon by you in evaluating the merits of investing in any securities or products. In addition, users should make an independent assessment of the legal, regulatory, tax, credit and accounting implications and determine, together with their own professional advisers, if any investment mentioned herein is believed to be suitable to their personal goals. Investors should ensure that they obtain all available relevant information before making any investment. It should be noted that investment involves risks, the value of investments and the income from them may fluctuate in accordance with market conditions and taxation agreements and investors may not get back the full amount invested. Both past performance and yields are not reliable indicators of current and future results.

Non-affiliated entities mentioned are for informational purposes only and should not be construed as an endorsement or sponsorship of J.P. Morgan Chase & Co. or its affiliates.

#### For J.P. Morgan Asset Management Clients:

J.P. Morgan Asset Management is the brand for the asset management business of JPMorgan Chase & Co. and its affiliates worldwide.

To the extent permitted by applicable law, we may record telephone calls and monitor electronic communications to comply with our legal and regulatory obligations and internal policies. Personal data will be collected, stored and processed by J.P. Morgan Asset Management in accordance with our privacy policies at <a href="https://am.jpmorgan.com/global/privacy">https://am.jpmorgan.com/global/privacy</a>.

#### ACCESSIBILITY

For U.S. only: If you are a person with a disability and need additional support in viewing the material, please call us at 1-800-343-1113 for assistance.

#### This communication is issued by the following entities:

In the United States, by J.P. Morgan Investment Management Inc. or J.P. Morgan Alternative Asset Management, Inc., both regulated by the Securities and Exchange Commission; in Latin America, for intended recipients' use only, by local J.P. Morgan entities, as the case may be.; in Canada, for institutional clients' use only, by JPMorgan Asset Management (Canada) Inc., which is a registered Portfolio Manager and Exempt Market Dealer in all Canadian provinces and territories except the Yukon and is also registered as an Investment Fund Manager in British Columbia, Ontario, Quebec and Newfoundland and Labrador. In the United Kingdom, by JPMorgan Asset Management (UK) Limited, which is authorized and regulated by the Financial Conduct Authority; in other European jurisdictions, by JPMorgan Asset Management (Europe) S.à r.l. In Asia Pacific ("APAC"), by the following issuing entities and in the respective jurisdictions in which they are primarily regulated: JPMorgan Asset Management (Asia Pacific) Limited, or JPMorgan Funds (Asia) Limited, or JPMorgan Asset Management (Singapore) Limited (Co. Reg. No. 197601586K), which this advertisement or publication has not been reviewed by the Monetary Authority of Singapore; JPMorgan Asset Management (Taiwan) Limited; JPMorgan Asset Management (Japan) Limited, which is a member of the Investment Trusts Association, Japan, the Japan Investment Advisers Association, Type II Financial Instruments Firms Association and the Japan Securities Dealers Association and is regulated by the Financial Services Agency (registration number "Kanto Local Finance Bureau (Financial Instruments Firm) No. 330"); in Australia, to wholesale clients only as defined in section 761A and 761G of the Corporations Act 2001 (Commonwealth), by JPMorgan Asset Management (Australia) Limited (ABN 55143832080) (AFSL 376919). For all other markets in APAC, to intended recipients only.

#### For J.P. Morgan Private Bank Clients:

#### ACCESSIBILITY

J.P. Morgan is committed to making our products and services accessible to meet the financial services needs of all our clients. Please direct any accessibility issues to the Private Bank Client Service Center at 1-866-265-1727.

#### LEGAL ENTITY, BRAND & REGULATORY INFORMATION

In the United States, bank deposit accounts and related services, such as checking, savings and bank lending, are offered by JPMorgan Chase Bank, N.A. Member FDIC.

JPMorgan Chase Bank, N.A. and its affiliates (collectively "JPMCB") offer investment products, which may include bank-managed investment accounts and custody, as part of its trust and fiduciary services. Other investment products and services, such as brokerage and advisory accounts, are offered through J.P. Morgan Securities LLC ("JPMS"), a member of <u>FINRA</u> and <u>SIPC</u>. Annuities are made available through Chase Insurance Agency, Inc. (CIA), a licensed insurance agency, doing business as Chase Insurance Agency Services, Inc. in Florida. JPMCB, JPMS and CIA are affiliated companies under the common control of JPM. Products not available in all states.

In Germany, this material is issued by J.P. Morgan SE, with its registered office at Taunustor 1 (TaunusTurm), 60310 Frankfurt am Main, Germany, authorized by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) and jointly supervised by the BaFin, the German Central Bank (Deutsche Bundesbank) and the European Central Bank (ECB). In Luxembourg, this material is issued by J.P. Morgan SE – Luxembourg Branch, with registered office at European Bank and Business Centre, 6 route de Treves, L-2633, Senningerberg, Luxembourg, authorized by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) and jointly supervised by the BaFin, the German Central Bank (ECB); J.P. Morgan SE – Luxembourg Branch, with registered office at European Bank and Business Centre, 6 route de Treves, L-2633, Senningerberg, Luxembourg, authorized by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) and jointly supervised by the BaFin, the German Central Bank (Deutsche Bundesbank) and the European Central Bank (ECB); J.P. Morgan SE – Luxembourg Branch, registered office at 25 Bank Street, Canary Wharf, London E14 5JP, authorized by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) and jointly supervised by the BaFin, the German Central Bank (Deutsche Bundesbank) and the European Central Bank (ECB); J.P. Morgan SE – London Branch, registered office at 25 Bank Street, Canary Wharf, London E14 5JP, authorized by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) and jointly supervised by the BaFin, the German Central Bank (Deutsche Bundesbank) and the European Central Bank (ECB); J.P. Morgan SE – London Branch, registered office at 25 Bank Street, Canary Wharf, London E14 5JP, authorized by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) and jointly supervised by the BaFin, the German Central Bank (Deutsche Bundesbank) and the European Central Bank (ECB); J.P. Morgan SE – London Branch is also supervised by the Financial Conduct Authority and Prudential Regulation Authority. In Spain, this materia

#### Access our full coronavirus analysis web portal here



distributed by J.P. Morgan SE, Sucursal en España, with registered office at Paseo de la Castellana, 31, 28046 Madrid, Spain, authorized by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) and jointly supervised by the BaFin, the German Central Bank (Deutsche Bundesbank) and the European Central Bank (ECB); J.P. Morgan SE, Sucursal en España is also supervised by the Spanish Securities Market Commission (CNMV); registered with Bank of Spain as a branch of J.P. Morgan SE under code 1567. In Italy, this material is distributed by J.P. Morgan SE – Milan Branch, with its registered office at Via Cordusio, n.3, Milan 20123, Italy, authorized by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) and jointly supervised by the BaFin, the German Central Bank (Deutsche Bundesbank) and the European Central Bank (ECB); J.P. Morgan SE – Milan Branch is also supervised by Bank of Italy and the Commissione Nazionale per le Società e la Borsa (CONSOB); registered with Bank of Italy as a branch of J.P. Morgan SE under code 8076; Milan Chamber of Commerce Registered Number: REA MI 2536325. In the Netherlands, this material is distributed by J.P. Morgan SE - Amsterdam Branch, with registered office at World Trade Centre, Tower B, Strawinskylaan 1135, 1077 XX, Amsterdam, The Netherlands, authorized by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) and jointly supervised by the BaFin, the German Central Bank (Deutsche Bundesbank) and the European Central Bank (ECB); J.P. Morgan SE – Amsterdam Branch is also supervised by De Nederlandsche Bank (DNB) and the Autoriteit Financiële Markten (AFM) in the Netherlands. Registered with the Kamer van Koophandel as a branch of J.P. Morgan SE under registration number 72610220. In Denmark, this material is distributed by J.P. Morgan SE – Copenhagen Branch, filial af J.P. Morgan SE, Tyskland, with registered office at Kalvebod Brygge 39-41, 1560 København V, Denmark, authorized by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) and jointly supervised by the BaFin, the German Central Bank (Deutsche Bundesbank) and the European Central Bank (ECB); J.P. Morgan SE – Copenhagen Branch, filial af J.P. Morgan SE, Tyskland is also supervised by Finanstilsynet (Danish FSA) and is registered with Finanstilsynet as a branch of J.P. Morgan SE under code 29010. In Sweden, this material is distributed by J.P. Morgan SE – Stockholm Bankfilial, with registered office at Hamngatan 15, Stockholm, 11147, Sweden, authorized by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) and jointly supervised by the BaFin, the German Central Bank (Deutsche Bundesbank) and the European Central Bank (ECB); J.P. Morgan SE - Stockholm Bankfilial is also supervised by Finansinspektionen (Swedish FSA); registered with Finansinspektionen as a branch of J.P. Morgan SE. In France, this material is distributed by JPMCB, Paris branch, which is regulated by the French banking authorities Autorité de Contrôle Prudentiel et de Résolution and Autorité des Marchés Financiers. In Switzerland, this material is distributed by J.P. Morgan (Suisse) SA, with registered address at rue de la Confédération, 8, 1211, Geneva, Switzerland, which is authorised and supervised by the Swiss Financial Market Supervisory Authority (FINMA), as a bank and a securities dealer in Switzerland. Please consult the following link to obtain information regarding J.P. Morgan's EMEA data protection policy: https://www.jpmorgan.com/privacy.

In **Hong Kong**, this material is distributed by **JPMCB**, **Hong Kong branch**. JPMCB, Hong Kong branch is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission of Hong Kong. In Hong Kong, we will cease to use your personal data for our marketing purposes without charge if you so request. In **Singapore**, this material is distributed by **JPMCB**, **Singapore branch**. JPMCB, Singapore branch is regulated by the Monetary Authority of Singapore. Dealing and advisory services and discretionary investment management services are provided to you by JPMCB, Hong Kong/Singapore branch (as notified to you). Banking and custody services are provided to you by JPMCB Singapore Branch. The contents of this document have not been reviewed by any regulatory authority in Hong Kong, Singapore or any other jurisdictions. You are advised to exercise caution in relation to this document. If you are in any doubt about any of the contents of this document, you should obtain independent professional advice. For materials which constitute product advertisement under the Securities and Futures Act and the Financial Advisers Act, this advertisement has not been reviewed by the Monetary Authority of Singapore. JPMorgan Chase Bank, N.A. is a national banking association chartered under the laws of the United States, and as a body corporate, its shareholder's liability is limited.

With respect to countries in Latin America, the distribution of this material may be restricted in certain jurisdictions. We may offer and/or sell to you securities or other financial instruments which may not be registered under, and are not the subject of a public offering under, the securities or other financial regulatory laws of your home country. Such securities or instruments are offered and/or sold to you on a private basis only. Any communication by us to you regarding such securities or instruments, including without limitation the delivery of a prospectus, term sheet or other offering document, is not intended by us as an offer to sell or a solicitation of an offer to buy any securities or instruments in any jurisdiction in which such an offer or a solicitation is unlawful. Furthermore, such securities or instruments may be subject to certain regulatory and/or contractual restrictions on subsequent transfer by you, and you are solely responsible for ascertaining and complying with such restrictions. To the extent this content makes reference to a fund, the Fund may not be publicly offering of any security, including the shares of the Fund, without previous registration at Brazilian Securities and Exchange Commission— CVM is completely prohibited. Some products or services contained in the materials might not be currently provided by the Brazilian and Mexican platforms.

JPMorgan Chase Bank, N.A. (JPMCBNA) (ABN 43 074 112 011/AFS Licence No: 238367) is regulated by the Australian Securities and Investment Commission and the Australian Prudential Regulation

Authority. Material provided by JPMCBNA in Australia is to "wholesale clients" only. For the purposes of this paragraph the term "wholesale client" has the meaning given in section 761G of the Corporations Act 2001 (Cth). Please inform us if you are not a Wholesale Client now or if you cease to be a Wholesale Client at any time in the future.

JPMorgan Chase Bank, N.A. (JPMCBNA) (ABN 43 074 112 011/AFS Licence No: 238367) is regulated by the Australian Securities and Investment Commission and the Australian Prudential Regulation Authority. Material provided by JPMCBNA in Australia is to "wholesale clients" only. For the purposes of this paragraph the term "wholesale client" has the meaning given in section 761G of the Corporations Act 2001 (Cth). Please inform us if you are not a Wholesale Client now or if you cease to be a Wholesale Client at any time in the future.

JPMS is a registered foreign company (overseas) (ARBN 109293610) incorporated in Delaware, U.S.A. Under Australian financial services licensing requirements, carrying on a financial services business in Australia requires a financial service provider, such as J.P. Morgan Securities LLC (JPMS), to hold an Australian Financial Services Licence (AFSL), unless an exemption applies. JPMS is exempt from the requirement to hold an AFSL under the Corporations Act 2001 (Cth) (Act) in respect of financial services it provides to you, and is regulated by the SEC, FINRA and CFTC under U.S. laws, which differ from Australian laws. Material provided by JPMS in Australia is to "wholesale clients" only. The information provided in this material is not intended to be, and must not be, distributed or passed on, directly or indirectly, to any other class of persons in Australia. For the purposes of this paragraph the term "wholesale client" has the meaning given in section 761G of the Act. Please inform us immediately if you are not a Wholesale Client at any time in the future.

This material has not been prepared specifically for Australian investors. It:

- May contain references to dollar amounts which are not Australian dollars;
- May contain financial information which is not prepared in accordance with Australian law or practices;
- May not address risks associated with investment in foreign currency denominated investments; and
- Does not address Australian tax issues.